An intriguing issue underlying the use of PSMA-radioligands in ccRCC patients is based on the overexpression of carboxypeptidase type II by intratumoral neovascular endothelial cells. The gene discussed is FOLH1; the disease is nonpapillary renal cell carcinoma.